Insulin detemir: a better basal insulin for the management of diabetes?

References

• Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care29, 1963–1972 (2006).
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.329, 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352, 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Gaede P, Sund-Andersen H, Parving HH et al. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med.358, 580–591 (2008).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standard of medial care in diabetes. Diabetes Care31(Suppl. 1), S12–S54 (2008).
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Davidson JA, Blonde L et al. ACE/AACE Diabetes Road Map Task Force. Endocr. Pract.13, 260–268 (2007).
   PubMedGoogle Scholar
• Halperin F, Ingelfinger JR, McMahon GT. Management of Type 2 diabetes – polling results. N. Engl. J. Med.358, E8 (2008).
   Google Scholar
• Havelund S, Plum A, Ribel U et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharmaceut. Res.21, 1498–1504 (2004).
   PubMed Web of Science ®Google Scholar
• Brunner GA, Sendlhofer G, Wutte A et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp. Clin. Endocrinol. Diabetes108, 100–105 (2000).
   PubMed Web of Science ®Google Scholar
• Kuerzel GU, Shukla U, Scholtz HE et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr. Med. Res. Opin.19, 34–40 (2003).
   PubMed Web of Science ®Google Scholar
• Fritsche A, Haring H. At last, a weight neutral insulin? Int J. Obes. Relat. Metab. Disord.28(Suppl. 2), S41–S46 (2004).
   PubMed Web of Science ®Google Scholar
• Wing RR, Klein R, Moss SE. Weight gain associated with improved glycemic control in population-based sample of subjects with Type 1 diabetes. Diabetes Care13, 1106–1109 (1990).
   Google Scholar
• DCCT Research Group. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care11, 567–573 (1988).
   PubMed Web of Science ®Google Scholar
• Salle A, Guilloteau G, Ryan M et al. Effect of insulin treatment on the body composition of Type 2 diabetic patients. Diabet. Med.21, 1849–1850 (2004).
   Google Scholar
• Tibaldi J. Actions of insulin beyond glycemic control: a perspective on insulin detemir. Adv. Ther.24, 868–882 (2007).
   PubMed Web of Science ®Google Scholar
• Scholtz HE, Pretorius SG, Wessels HD et al. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia48, 1988–1995 (2005).
   PubMed Web of Science ®Google Scholar
• Markussen J, Havelund S, Kurtzhals P et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia39, 281–288 (1996).
   PubMed Web of Science ®Google Scholar
• Hompesch M, Troupin B, Heise T et al. Time–action profile of insulin detemir and NPH insulin in patients with Type 2 diabetes from different ethnic groups. Diabetes Obes. Metab.8, 568–573 (2006).
   PubMed Web of Science ®Google Scholar
• Bott S, Tusek C, Jacobsen LV et al. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes. Diabet. Med.23, 522–528 (2006).
   PubMed Web of Science ®Google Scholar
• Wutte A, Plank J, Bodenlenz M et al. Proportional dose–response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with Type 1 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes115, 461–467 (2007).
   PubMed Web of Science ®Google Scholar
• Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose–response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care28, 1107–1112 (2005).
   PubMed Web of Science ®Google Scholar
• Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with Type 1 diabetes. Diabetes53, 1614–1620 (2004).
   PubMed Web of Science ®Google Scholar
• Klein O, Lynge J, Endahl L et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in Type 2 diabetes. Diabetes Obes. Metab.9, 290–299 (2007).
   PubMed Web of Science ®Google Scholar
• Porcellati F, Rossetti P, Busciantella NR et al. Comparison of pharmacokinetics and dynamic of the long-acting insulin analogs glargine and detemir at steady state in Type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care30, 2447–2452 (2007).
   PubMed Web of Science ®Google Scholar
• Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes. Metab.9, 648–659 (2007).
   PubMed Web of Science ®Google Scholar
• King AB, Armstrong DU. A randomized, crossover, double-blind comparison of insulin detemir and insulin glargine daily blood glucose profiles in subjects with Type 2 diabetes. Diabetes57(Suppl. 1), A130 (2008).
   Google Scholar
• Danne T, Lupke K, Walte K et al. Insulin detemir is characterized by a consistent pharamcokinetic profile across age-groups in children, adolescents, and adults with Type 1 diabetes. Diabetes Care26, 3087–3092 (2003).
   PubMed Web of Science ®Google Scholar
• Kutzhals P. How to achieve a predictable basal insulin? Diabetes Metab.31(4), S25–S33 (2005).
   Google Scholar
• Vague P, Selam J-L, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with Type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care26, 590–596 (2003).
   PubMed Web of Science ®Google Scholar
• Home PK, Bartley P, Russell-Jones D et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with Type 1 diabetes. Diabetes Care27, 1081–1087 (2004).
   PubMed Web of Science ®Google Scholar
• Bartley PC, Bogoev M, Larsen J et al. Long-term efficacy and safety of insulin detemir compared with neutral protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal–bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet. Med.25, 442–449 (2008).
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Simpson R, Hylleberg B et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with Type 1 diabetes mellitus using a basal–bolus regimen. Clin. Ther.26, 724–736 (2004).
   PubMed Web of Science ®Google Scholar
• Standl E, Lang H, Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal–bolus therapy for the treatment of Type 1 diabetes. Diabetes Technol. Ther.6, 579–588 (2004).
   PubMedGoogle Scholar
• Robertson KJ, Schoenle E, Gucev Z et al. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet. Med.24, 27–34 (2007).
   PubMed Web of Science ®Google Scholar
• De Leeuw I, Vague P, Selam JL et al. Insulin detemir used in basal–bolus therapy in people with Type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes. Metab.7, 73–82 (2005).
   PubMed Web of Science ®Google Scholar
• Hermansen K, Madsbad S, Perrild H et al. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized, open, crossover trial in Type 1 diabetic subjects on basal-bolus therapy. Diabetes Care24, 296–301 (2001).
   PubMed Web of Science ®Google Scholar
• Kolendorf K, Ross GP, Pavlic-Renar I et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet. Med.23, 729–735 (2006).
   PubMed Web of Science ®Google Scholar
• Pieber TR, Treichel HC, Robertson LI et al. Insulin detemir plus insulin aspart is associated with less risk of major as well as nocturnal hypoglycemia than insulin glargine plus insulin aspart at comparable levels of glycemic control in Type 1 diabetes. Diabetologia48, A92 (2005).
   Google Scholar
• Hermansen K, Davies M, Derezinski T et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with Type 2 diabetes. Diabetes Care29, 1269–1274 (2006).
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A, Charpentier G, Clauson P et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled Type 2 diabetes. Clin. Ther.28, 1569–1581 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home PD et al. A randomized, 52-week, treat-to-target trail comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with Type 2 diabetes. Diabetologia51, 408–416 (2008).
   PubMed Web of Science ®Google Scholar
• Raskin P, Chaykin L, Mak C et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a treat-to-target study in people with Type 2 diabetes. Diabetic Med.23(Suppl. 4), 341–342 (2006).
   Google Scholar
• Luddeke HJ, Sreenana S, Aczel S et al. PREDICTIVE – a global, prospective observational study to evaluate insulin detemir treatment in Types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabet. Obes. Metab.9(3), 428–434 (2007).
   PubMed Web of Science ®Google Scholar
• Dornhorst A, Luddeke HJ, Honka M et al. Safety and efficacy of insulin detemir basal–bolus therapy in Type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr. Med. Res. Opin.24, 369–376 (2008).
   PubMed Web of Science ®Google Scholar
• Dornhorst A, Luddeke HJ, Sreenan S et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from Type 1 and Type 2 diabetes patients in the PREDICTIVE European cohort. Int. J. Clin. Pract.61523–528 (2007).
   PubMed Web of Science ®Google Scholar
• King A, Armstrong D. A prospective evaluation of insulin dosing recommendations in patients with Type 1 diabetes at near normal glucose control: basal dosing. J. Diabetes Sci. Technol.1, 36–41 (2007).
   Google Scholar
• Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care30, 203–209 (2007).
   Google Scholar